Please ensure Javascript is enabled for purposes of website accessibility

Why Inovio Pharmaceuticals Is Cratering Today

By George Budwell - Updated Mar 10, 2020 at 11:07AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A famous short-seller called out Inovio on Twitter yesterday.

What happened

Inovio Pharmaceuticals (INO -0.48%), a DNA-based immunotherapy and vaccine company, is having another wild trading session Tuesday morning. Out of the gate, Inovio's stock shot up by 10.7% on heavy volume. But within a matter of minutes, the biotech quickly reversed course, with its shares now down by 30% as of 10:12 a.m. EDT. 

So what

What's behind this whipsaw action in Inovio's stock? Inovio's shares were up by a stately 327% for the year as of last Friday. Investors were bidding up this tiny biotech in response to the hype surrounding its experimental COVID-19 vaccine, dubbed INO-4800. Specifically, the company previously announced that it had developed a viable vaccine candidate within just three hours of the publication of the virus' genetic sequence. As the world is clamoring for a COVID-19 vaccine, Inovio, in theory at least, may have a veritable goldmine on its hands.

A stock chart drawn in chalk moving up, and then down.

Image source: Getty Images.

Short-seller Citron Research apparently sees it a different way, however. In a tweet yesterday afternoon, Citron called Inovio's claims about developing a vaccine in a matter of hours "ludicrous" and "dangerous." The firm also noted that it believes Inovio's shares will fall back to the $2 range once the hype subsides. That's a harsh call to be sure, but Inovio does have a history of jumping on the bandwagon of these high-profile infectious diseases.   

Now what

What's the best course of action for shareholders today? Inovio's run-up on this COVID-19 vaccine news is probably way overdone. In a best-case scenario, Inovio's vaccine might be ready for the market three years from now, and that's likely an overly optimistic time line. In brief, there's no solid evidence to believe that Inovio will ever financially benefit from its experimental COVID-19 vaccine -- that is, besides some one-time grant money. As such, it might be a wise idea to watch this extremely volatile biotech stock from the safety of the sidelines. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Inovio Pharmaceuticals, Inc. Stock Quote
Inovio Pharmaceuticals, Inc.
INO
$2.06 (-0.48%) $0.01

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
323%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/07/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.